NeoGenomics Plunges 12% as Leadership Shakeup and Q3 Beat Fail to Impress
NEO has more than doubled off its 52-week low of $7.065.
Summary
NeoGenomics shares fell more than 12% on Tuesday, the worst one-day drop in over a year, after the company announced CEO succession plans and preliminary Q3 revenue of about $209M, which beat the $206M consensus. President and COO Warren Stone will become CEO on Jan 4, 2027, replacing Tony Zook, who becomes executive chair. The stock's sharp decline despite the beat and raised full-year outlook suggests investors had priced in even stronger results after an 86% year-over-year run. BTIG upgraded the stock to Buy from Neutral with a $28 target, and Needham raised its target to $22 from $19, but the market reaction was decisively negative. This follows yesterday's announcement of the same leadership transition and Q3 preannouncement, but today's move adds a new trading session's price action and analyst upgrades.
At the time of this announcement, NEO was trading at $16.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $7.07 to $20.15. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.